{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:19:37Z","timestamp":1791314377724,"version":"4.3.1"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,12,1]],"date-time":"2016-12-01T00:00:00Z","timestamp":1480550400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"ZonMw","award":["40-41900-98-018"],"award-info":[{"award-number":["40-41900-98-018"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1016\/j.biopha.2016.09.007","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T07:00:20Z","timestamp":1474009220000},"page":"93-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington\u2019s disease"],"prefix":"10.1016","volume":"84","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3395-6768","authenticated-orcid":false,"given":"Jo\u00e3o","family":"Casaca-Carreira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lodewijk J.A.","family":"Toonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melvin M.","family":"Evers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Jahanshahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willeke M.C.","family":"van-Roon-Mom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasin","family":"Temel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2016.09.007_bib0005","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/7854_2013_245","article-title":"Transgenic rat models of Huntington\u2019s disease","volume":"22","author":"Carreira","year":"2015","journal-title":"Curr. Top. Behav. Neurosci"},{"issue":"5940","key":"10.1016\/j.biopha.2016.09.007_bib0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/306234a0","article-title":"A polymorphic DNA marker genetically linked to Huntington's disease","volume":"306","author":"Gusella","year":"1983","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2016.09.007_bib0015","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","author":"MacDonald","year":"1993","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2016.09.007_bib0020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.biopha.2016.09.007_bib0025","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00005072-199805000-00001","article-title":"Huntington disease","volume":"57","author":"Vonsattel","year":"1998","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"3","key":"10.1016\/j.biopha.2016.09.007_bib0030","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"issue":"2","key":"10.1016\/j.biopha.2016.09.007_bib0035","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1172\/JCI45130","article-title":"Oligonucleotide therapeutic approaches for Huntington disease","volume":"121","author":"Sah","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"9","key":"10.1016\/j.biopha.2016.09.007_bib0040","doi-asserted-by":"crossref","first-page":"e24308","DOI":"10.1371\/journal.pone.0024308","article-title":"Targeting several CAG expansion diseases by a single antisense oligonucleotide","volume":"6","author":"Evers","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.biopha.2016.09.007_bib0045","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.cell.2012.08.002","article-title":"Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression","volume":"150","author":"Yu","year":"2012","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2016.09.007_bib0050","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1089\/nat.2013.0452","article-title":"Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification","volume":"24","author":"Evers","year":"2014","journal-title":"Nucleic Acid Ther."},{"issue":"6","key":"10.1016\/j.biopha.2016.09.007_bib0055","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.cell.2006.04.026","article-title":"Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin","volume":"125","author":"Graham","year":"2006","journal-title":"Cell"},{"issue":"Pt. 4","key":"10.1016\/j.biopha.2016.09.007_bib0060","first-page":"919","article-title":"Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin","volume":"132","author":"Pouladi","year":"2009","journal-title":"Brain"},{"key":"10.1016\/j.biopha.2016.09.007_bib0065","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.addr.2015.03.008","article-title":"Antisense oligonucleotides in therapy for neurodegenerative disorders","volume":"87","author":"Evers","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.biopha.2016.09.007_bib0070","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1152\/physrev.00041.2009","article-title":"Molecular mechanisms and potential therapeutical targets in Huntington\u2019s disease","volume":"90","author":"Zuccato","year":"2010","journal-title":"Physiol. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2016.09.007_bib0075","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/0092-8674(95)90542-1","article-title":"Targeted disruption of the Huntington\u2019s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes","volume":"81","author":"Nasir","year":"1995","journal-title":"Cell"},{"issue":"5222","key":"10.1016\/j.biopha.2016.09.007_bib0080","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.7618107","article-title":"Inactivation of the mouse Huntington\u2019s disease gene homolog Hdh","volume":"269","author":"Duyao","year":"1995","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biopha.2016.09.007_bib0085","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/81593","article-title":"Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice","volume":"26","author":"Dragatsis","year":"2000","journal-title":"Nat. Genet."},{"issue":"13","key":"10.1016\/j.biopha.2016.09.007_bib0090","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1093\/hmg\/ddg169","article-title":"Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease","volume":"12","author":"Slow","year":"2003","journal-title":"Hum. Mol. Genet."},{"issue":"6","key":"10.1016\/j.biopha.2016.09.007_bib0095","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.neuron.2012.05.009","article-title":"Sustained therapeutic reversal of Huntington\u2019s disease by transient repression of huntingtin synthesis","volume":"74","author":"Kordasiewicz","year":"2012","journal-title":"Neuron"},{"issue":"12","key":"10.1016\/j.biopha.2016.09.007_bib0100","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/mt.2014.153","article-title":"In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides","volume":"22","author":"Southwell","year":"2014","journal-title":"Mol. Ther."},{"issue":"21","key":"10.1016\/j.biopha.2016.09.007_bib0105","doi-asserted-by":"crossref","first-page":"9634","DOI":"10.1093\/nar\/gkt725","article-title":"Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS","volume":"41","author":"Ostergaard","year":"2013","journal-title":"Nucleic Acids Res."},{"issue":"17","key":"10.1016\/j.biopha.2016.09.007_bib0110","doi-asserted-by":"crossref","first-page":"9591","DOI":"10.1073\/pnas.97.17.9591","article-title":"Restoration of hemoglobin A synthesis in erythroid cells from peripheral blood of thalassemic patients","volume":"97","author":"Lacerra","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"11","key":"10.1016\/j.biopha.2016.09.007_bib0115","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/sj.embor.7400273","article-title":"Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation","volume":"5","author":"Nissim-Rafinia","year":"2004","journal-title":"EMBO Rep."},{"issue":"5","key":"10.1016\/j.biopha.2016.09.007_bib0120","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/humu.20303","article-title":"Aberrant splicing in the ocular albinism type 1 gene (OA1\/GPR143) is corrected in vitro by morpholino antisense oligonucleotides","volume":"27","author":"Vetrini","year":"2006","journal-title":"Hum. Mutat."},{"issue":"26","key":"10.1016\/j.biopha.2016.09.007_bib0125","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1056\/NEJMoa073108","article-title":"Local dystrophin restoration with antisense oligonucleotide PRO051","volume":"357","author":"van Deutekom","year":"2007","journal-title":"N. Engl. J. Med."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216311088?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216311088?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:36:33Z","timestamp":1773873393000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332216311088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12]]},"references-count":25,"alternative-id":["S0753332216311088"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2016.09.007","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2016,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2016.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}